Categories
Business

WildHorse Resource Development Corporation (NYSE:WRD) FCF Growth Reaches

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow.  The FCF Growth of WildHorse Resource Development Corporation (NYSE:WRD) is .  Free cash flow (FCF) is the cash produced by the company minus capital expenditure.  This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends.  The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow.  The FCF Score of WildHorse Resource Development Corporation (NYSE:WRD) is .  Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

For the novice investor, the stock market can sometimes be a scary place. Many investors may be ready to jump into the ring, but they might not have the proper training. Finding a stock market strategy that puts the investor on the winning side is not an easy task. There is a plentiful amount of information regarding the equity market. Knowing what information to focus on can be the key to sustained success. Investors who are able to sift through the noise and stick to a sturdy stock picking plan, may be in a much better position when tough portfolio decisions need to be made. Many investors will instinctually want to jump in to a stock that has taken off running. Sometimes this may work out positively, but it can also lead to significant losses and second guessing. If all the proper research is completed, investors may feel more at ease with their selections going forward. Of course there will be times when the research does not turn into expected profits, but knowing how to let go of those stocks may help the investor in the long run.  

Checking in on some valuation rankings, WildHorse Resource Development Corporation (NYSE:WRD) has a Value Composite score of 36. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 44.

Watching some historical volatility numbers on shares of WildHorse Resource Development Corporation (NYSE:WRD), we can see that the 12 month volatility is presently 56.0714. The 6 month volatility is 61.3403, and the 3 month is spotted at 70.1441. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. 

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength.  The score helps determine if a company’s stock is valuable or not.  The Piotroski F-Score of WildHorse Resource Development Corporation (NYSE:WRD) is 4.  A score of nine indicates a high value stock, while a score of one indicates a low value stock.  The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings.  It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue.  The score is also determined by change in gross margin and change in asset turnover.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price.  The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital.  The MF Rank of WildHorse Resource Development Corporation (NYSE:WRD) is 10309.  A company with a low rank is considered a good company to invest in.  The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Shifting gears, we can see that WildHorse Resource Development Corporation (NYSE:WRD) has a Q.i. Value of 53. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements.  The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth.  The C-Score of WildHorse Resource Development Corporation (NYSE:WRD) is 2.  The score ranges on a scale of -1 to 6.  If the score is -1, then there is not enough information to determine the C-Score.  If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.

Ratios

The Current Ratio of WildHorse Resource Development Corporation (NYSE:WRD) is 0.32.  The Current Ratio is used by investors to determine whether a company can pay short term and long term debts.  The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities.  A high current ratio indicates that the company might have trouble managing their working capital.  A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

The Leverage Ratio of WildHorse Resource Development Corporation (NYSE:WRD) is 0.387788.  Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two.  Companies take on debt to finance their day to day operations.  The leverage ratio can measure how much of a company’s capital comes from debt.  With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.

Return on Assets

There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for WildHorse Resource Development Corporation (NYSE:WRD) is -0.054964. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Earnings to Price yield of WildHorse Resource Development Corporation NYSE:WRD is -0.099181.  This is calculated by taking the earnings per share and dividing it by the last closing share price.  This is one of the most popular methods investors use to evaluate a company’s financial performance.  Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company.  The Earnings Yield for WildHorse Resource Development Corporation NYSE:WRD is 0.027524.  Earnings Yield helps investors measure the return on investment for a given company.  Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value.  The Earnings Yield Five Year average for WildHorse Resource Development Corporation (NYSE:WRD) is .

The stock investing process may seem intimidating to those just starting out. New investors may have a lot to learn, and they may be wondering where to start. Because there are so many different stock picking strategies, it can be hard to find one specific one to latch on to. Keeping things simple might be a good way to approach the market for beginners. The day to day market happenings can get overwhelming not only for amateurs but professional investors as well. Finding that first little advantage can make all the difference when picking stocks. Many new investors may have the tendency to make too many trades at first without doing the proper research. Easing in to the process may give some much needed perspective for attaining long-term success in the stock market.

Categories
Business

How Are Analysts Approaching Shares of Main Street Capital Corporation (NYSE:MAIN)?

Main Street Capital Corporation (NYSE:MAIN) currently has an Average Broker Rating of -33.41. This number is based on the 2.54 sell-side firms polled by Zacks. The ABR rank within the industry stands at 9.29.   

Analysts on a consensus basis are expecting that the stock will reach $39.25 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry or sector of the economy. They exert considerable influence in today’s marketplace. Analysts’ recommendations or reports can influence the price of a company’s stock—especially when the recommendations are widely disseminated through television appearances or through other electronic and print media. The mere mention of a company by a popular analyst can temporarily cause its stock to rise or fall—even when nothing about the company’s prospects or fundamentals has recently changed.

Analysts often use a variety of terms—buy, strong buy, near-term or long-term accumulate, near-term or long-term over-perform or under-perform, neutral, hold—to describe their recommendations. But the meanings of these terms can differ from firm to firm. Rather than make assumptions, investors should carefully read the definitions of all ratings used in each research report. They should also consider the firm’s disclosures regarding what percentage of all ratings fall into either “buy,” “hold/neutral,” and “sell” categories.

Dedicated investors tend to spend a lot of time trying to decipher the correct procedure for beating the stock market. This may involve figuring out a proper strategy, and deciding which stocks to start with when constructing a portfolio. Building a portfolio does not have to be a frantic race. In fact, not rushing into things may end up putting the investor in a good position to succeed. There are times when tough decisions need to be made when dealing with the equity market. Spending enough time to assess all the possibilities before making an investing decision may pay off down the road. As most investors know, there is no magic formula for coming out a winner in the stock market. Acquiring the most possible knowledge about the markets and individual stocks can play a vital role in the long-term success of the individual investor. 

Research analysts are predicting that Main Street Capital Corporation (NYSE:MAIN) will report earnings of $0.59 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Main Street Capital Corporation (NYSE:MAIN) closed the last session at $23.58 and sees an average of 1472279 shares trade hands in each session. The 52-week low of the stock stands at $15.74 while the current level stands at 0.85% of the 52-week High-Low range. Looking further out we can see that the stock has moved -38.82% over the past 12 weeks and -45.53% year to date.

Most recently Main Street Capital Corporation (NYSE:MAIN) posted quarterly earnings of $0.62 which compared to the sell-side estimates of 0.6. The stock’s 12-month trailing earnings per share stands at $2.51. Shares have moved $0.06357 over the past month and more recently, $173 over the past week heading into the earnings announcement. There are 3 analyst projections that were taken into consideration from respected brokerage firms.

Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares. 

5 analysts rate Main Street Capital Corporation a Buy or Strong Buy, which is 2% of all the analyst ratings.

Categories
Business

Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) By The Numbers: How Healthy Is This Stock? FCF Runs to 0.673456

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value.  Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents.  The average FCF of a company is determined by looking at the cash generated by operations of the company.  The Free Cash Flow Yield 5 Year Average of Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is -0.070675. 

Often times, investors are faced with challenging portfolio decisions. Maybe there are a few stocks that have outperformed expectations by a large margin. Investors may be hesitant to exit a position with the fear that the stock may have much more room to run. Investors may have to decide if the time is right to cash in and take some profits, or hold out for further gains. On the other end, investors may have a few duds in the portfolio. Cutting ties with certain underperformers can be a tough decision. It may be hard for an investor to sell a position that they thought for sure was going to pan out and provide gains. Being able to detach from a certain position may help ease the possibility of even more frustration later down the line if the stock doesn’t bounce back.

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength.  The score helps determine if a company’s stock is valuable or not.  The Piotroski F-Score of Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is 4.  A score of nine indicates a high value stock, while a score of one indicates a low value stock.  The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings.  It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue.  The score is also determined by change in gross margin and change in asset turnover.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price.  The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital.  The MF Rank of Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is 16315.  A company with a low rank is considered a good company to invest in.  The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Shifting gears, we can see that Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) has a Q.i. Value of 75. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

Checking in on some valuation rankings, Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) has a Value Composite score of 92. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 96.

Watching some historical volatility numbers on shares of Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA), we can see that the 12 month volatility is presently 67.7699. The 6 month volatility is 69.7361, and the 3 month is spotted at 70.1678. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period. 

The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements.  The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth.  The C-Score of Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is 1.  The score ranges on a scale of -1 to 6.  If the score is -1, then there is not enough information to determine the C-Score.  If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.

Shareholder Yield, Shareholder Yield (Mebane Faber)

The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. The Shareholder Yield of Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is -1.965218. This percentage is calculated by adding the dividend yield plus the percentage of shares repurchased. Dividends are a common way that companies distribute cash to their shareholders. Similarly, cash repurchases and a reduction of debt can increase the shareholder value, too. Another way to determine the effectiveness of a company’s distributions is by looking at the Shareholder yield (Mebane Faber). The Shareholder Yield (Mebane Faber) of Dicerna Pharmaceuticals, Inc. NasdaqGS:DRNA is -0.21878. This number is calculated by looking at the sum of the dividend yield plus percentage of sales repurchased and net debt repaid yield.

Valuation

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Dicerna Pharmaceuticals, Inc. NasdaqGS:DRNA is 4.2883. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is -13.603628. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is -7.207235. This ratio is found by taking the current share price and dividing by earnings per share.

Traders might be paying extra attention to the technicals as they look to spot buying opportunities in the stock market. Because there are so many different strategies that traders can use, it may be difficult to pinpoint the correct avenue. New traders might choose to focus on one or two main indicators when just starting out. With time and experience, many traders will use a combination of various indicators when setting up their persona charts. It may be wise for traders to remember that what has worked for someone else in the past may not work for them in the future.

Categories
Business

Do Analysts See Any Upside to Argo Group International Holdings, Ltd. (:ARGO)?

Argo Group International Holdings, Ltd. (:ARGO) currently has an Average Broker Rating of -30.15. The ABR rank within the industry stands at -10.77. This number is based on the 2.4 sell-side firms polled by Zacks.  

Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR. 

As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.

Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.

For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.

Analysts on a consensus basis are expecting that the stock will reach $79 within the year.

Dedicated investors tend to spend a lot of time trying to decipher the correct procedure for beating the stock market. This may involve figuring out a proper strategy, and deciding which stocks to start with when constructing a portfolio. Building a portfolio does not have to be a frantic race. In fact, not rushing into things may end up putting the investor in a good position to succeed. There are times when tough decisions need to be made when dealing with the equity market. Spending enough time to assess all the possibilities before making an investing decision may pay off down the road. As most investors know, there is no magic formula for coming out a winner in the stock market. Acquiring the most possible knowledge about the markets and individual stocks can play a vital role in the long-term success of the individual investor. 

Research analysts are predicting that Argo Group International Holdings, Ltd. (:ARGO) will report earnings of $0.58 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Argo Group International Holdings, Ltd. (:ARGO) closed the last session at $34.86 and sees an average of 335797 shares trade hands in each session. The 52-week low of the stock stands at $31 while the current level stands at 0.71% of the 52-week High-Low range. Looking further out we can see that the stock has moved -40.36% over the past 12 weeks and -47.94% year to date.

Most recently Argo Group International Holdings, Ltd. (:ARGO) posted quarterly earnings of $-2.15 which compared to the sell-side estimates of -2.18. The stock’s 12-month trailing earnings per share stands at $-0.93. Shares have moved $0.12211 over the past month and more recently, $190 over the past week heading into the earnings announcement. There are 3 analyst projections that were taken into consideration from respected brokerage firms.

Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares. 

5 analysts rate Argo Group International Holdings, Ltd. a Buy or Strong Buy, which is 2% of all the analyst ratings.

Categories
Business

Bark or Bite? What is The Street Consensus on Lincoln National Corporation (NYSE:LNC)

Lincoln National Corporation (NYSE:LNC) currently has an Average Broker Rating of -40.11. The ABR rank within the industry stands at -24.44. This number is based on the 1.94 sell-side firms polled by Zacks.  

Each brokerage research report carries with it some form of recommendation. The brokerage firms may use different lingo for their rating systems (like saying Outperform instead of Buy), but they can all be properly sorted into our 5 level classification system that is now the industry standard. Each of the 5 classifications has a value associated with it to help compute the ABR. 

As the name implies the ABR will show you the Average of Brokerage Recommendations on a given stock. The benefit is that you quickly get a snapshot of where Wall Street stands on a stock without having to read a mountain of research reports.

Broker recommendations are made by brokerage firms (for example, JP Morgan) and are not an outright recommendation to buy or sell a share, but instead give an indication of how the broker thinks the company will perform relative to its sector. Their recommendations are issued over a particular period of time. The recommendations provided in the Research Centre are shown on a 75 day rolling basis. Each brokerage firm has its own way of rating that may make it difficult to compare broker recommendations between the brokerage houses.

For example, at one brokerage “buy” may be the strongest recommendation, while at another “buy” could be second to a “strong buy” rating. The second-highest ratings also have a number of different other names: “accumulate”, “outperform”, “moderate buy” or “overweight”.

Analysts on a consensus basis are expecting that the stock will reach $56.67 within the year.

Technical investors generally rely heavily on price charts to help spot potential trades. Chartists will often try to interpret past movements with the goal of trying to gauge the future share price movements. Some charts can be extremely complex while others may be quite simple. Many traders will spend countless hours studying the signals to try to spot optimal entry and exit points. There are many different indicators that technical analysts can follow. Some traders will use standalone signals, and others will use a robust combination. Getting into the nitty-gritty of charting can be overwhelming for the beginner. Taking the time to completely understand what the charts are saying can be the difference between a big win and a major loss.

Most recently Lincoln National Corporation (NYSE:LNC) posted quarterly earnings of $2.41 which compared to the sell-side estimates of 2.44. The stock’s 12-month trailing earnings per share stands at $9.13. Shares have moved $0.06526 over the past month and more recently, $192 over the past week heading into the earnings announcement. There are 4 analyst projections that were taken into consideration from respected brokerage firms.

Technical investors generally rely heavily on price charts to help spot potential trades. Chartists will often try to interpret past movements with the goal of trying to gauge the future share price movements. Some charts can be extremely complex while others may be quite simple. Many traders will spend countless hours studying the signals to try to spot optimal entry and exit points. There are many different indicators that technical analysts can follow. Some traders will use standalone signals, and others will use a robust combination. Getting into the nitty-gritty of charting can be overwhelming for the beginner. Taking the time to completely understand what the charts are saying can be the difference between a big win and a major loss.

Buy Ratings
9 analysts rate Lincoln National Corporation a Buy or Strong Buy, which is 5% of all the analyst ratings.

Earnings
Research analysts are predicting that Lincoln National Corporation (NYSE:LNC) will report earnings of $2.27 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Lincoln National Corporation (NYSE:LNC) closed the last session at $27.46 and sees an average of 4427618 shares trade hands in each session. The 52-week low of the stock stands at $17.06 while the current level stands at 1.9% of the 52-week High-Low range. Looking further out we can see that the stock has moved -42.47% over the past 12 weeks and -54.04% year to date.

Every investor strives to maximize returns in the stock market. To achieve success in the market, investors may take many different paths. Because there are so many different strategies, one investor’s road may end up being quite different than another. Over time, the investor may have to overcome various difficulties. Trading the stock market can indeed be exhilarating, but it can also cause lots of strife. Some investors may be able to be much more aggressive when creating the stock portfolio. Others may have a much lower risk threshold and choose to play it a bit safer. Because humans are prone to error, there may be many mistakes made along the way. Investors who are able to identify mistakes and learn from them may find themselves in a much better position down the road.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.

Categories
Business

Analysts Poring Over the Numbers on LCI Industries (:LCII)

LCI Industries (:LCII) currently has an Average Broker Rating of -20.5. This number is based on the 1.5 sell-side firms polled by Zacks. The ABR rank within the industry stands at 25.

Analysts often use a number of terms—buy, strong buy, near-term or long-term accumulate, near-term or long-term over-perform or under-perform, neutral, hold— to describe their recommendations. But the definitions of these terms can differ from company to company. Instead of making assumptions, investors should read the definitions of all ratings used in each analyst report. They should also consider the company’s disclosures regarding what percentage of all ratings fall into either “buy,” “hold/neutral,” and “sell” groups.

Analysts on a consensus basis are expecting that the stock will reach $107 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry or sector of the economy. They exert considerable influence in today’s marketplace. Analysts’ recommendations or reports can influence the price of a company’s stock—especially when the recommendations are widely disseminated through television appearances or through other electronic and print media. The mere mention of a company by a popular analyst can temporarily cause its stock to rise or fall—even when nothing about the company’s prospects or fundamentals has recently changed.When active traders find an opening to get in on a stock they think is about to make a move, they may try to buy up as much as they can before the price moves back outside the buying range. This buying may be seen when the stock market dips after a bearish move. Spotting these buying conditions and being able to make a timely move can help the trader take advantage of various market scenarios. Winning traders are typically ready to pounce on any opportunity they find in the stock market.

LCI Industries (:LCII) closed the last session at $65.98 and sees an average of 222470 shares trade hands in each session. The 52-week low of the stock stands at $58.69 while the current level stands at 1.38% of the 52-week High-Low range. Looking further out we can see that the stock has moved -33.29% over the past 12 weeks and -38.7% year to date.

Research analysts are predicting that LCI Industries (:LCII) will report earnings of $1.61 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Most recently LCI Industries (:LCII) posted quarterly earnings of $1.14 which compared to the sell-side estimates of 1.1. The stock’s 12-month trailing earnings per share stands at $5.83. Shares have moved $0.28462 over the past month and more recently, $163 over the past week heading into the earnings announcement. There are 3 analyst projections that were taken into consideration from respected brokerage firms.

6 analysts rate LCI Industries a Buy or Strong Buy, which is 5% of all the analyst ratings.

With so many different stock trading strategies to choose from, new investors may become overwhelmed when presented with all the possible options. Some investors will choose to rely on the expertise of professionals, while others will try to have a go at it on their own. Investors who prefer to do their own research and make their own investment decisions are quite common these days. Of course there is no set in stone way to properly trade the stock market. Markets and economic situations are constantly changing. Staying on top of all the latest information and global developments can be challenging. Investors who are able to stay the course and put in the required time might be able to eventually give themselves a leg up in the future.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.

Categories
Business

Bark or Bite? What is The Street Consensus on TD Ameritrade Holding Corporation (NYSE:AMTD)

TD Ameritrade Holding Corporation (NYSE:AMTD) currently has an Average Broker Rating of -13.39. This number is based on the 2.55 sell-side firms polled by Zacks. The ABR rank within the industry stands at 6.67.   

Analysts on a consensus basis are expecting that the stock will reach $43.44 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry or sector of the economy. They exert considerable influence in today’s marketplace. Analysts’ recommendations or reports can influence the price of a company’s stock—especially when the recommendations are widely disseminated through television appearances or through other electronic and print media. The mere mention of a company by a popular analyst can temporarily cause its stock to rise or fall—even when nothing about the company’s prospects or fundamentals has recently changed.

Analysts often use a variety of terms—buy, strong buy, near-term or long-term accumulate, near-term or long-term over-perform or under-perform, neutral, hold—to describe their recommendations. But the meanings of these terms can differ from firm to firm. Rather than make assumptions, investors should carefully read the definitions of all ratings used in each research report. They should also consider the firm’s disclosures regarding what percentage of all ratings fall into either “buy,” “hold/neutral,” and “sell” categories.

Dedicated investors tend to spend a lot of time trying to decipher the correct procedure for beating the stock market. This may involve figuring out a proper strategy, and deciding which stocks to start with when constructing a portfolio. Building a portfolio does not have to be a frantic race. In fact, not rushing into things may end up putting the investor in a good position to succeed. There are times when tough decisions need to be made when dealing with the equity market. Spending enough time to assess all the possibilities before making an investing decision may pay off down the road. As most investors know, there is no magic formula for coming out a winner in the stock market. Acquiring the most possible knowledge about the markets and individual stocks can play a vital role in the long-term success of the individual investor. 

Research analysts are predicting that TD Ameritrade Holding Corporation (NYSE:AMTD) will report earnings of $0.8 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

TD Ameritrade Holding Corporation (NYSE:AMTD) closed the last session at $34.51 and sees an average of 7458160 shares trade hands in each session. The 52-week low of the stock stands at $28.68 while the current level stands at 1.23% of the 52-week High-Low range. Looking further out we can see that the stock has moved -21.12% over the past 12 weeks and -31.68% year to date.

Most recently TD Ameritrade Holding Corporation (NYSE:AMTD) posted quarterly earnings of $0.74 which compared to the sell-side estimates of 0.77. The stock’s 12-month trailing earnings per share stands at $3.76. Shares have moved $0.42233 over the past month and more recently, $101 over the past week heading into the earnings announcement. There are 6 analyst projections that were taken into consideration from respected brokerage firms.

Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares. 

11 analysts rate TD Ameritrade Holding Corporation a Buy or Strong Buy, which is 3% of all the analyst ratings.

Categories
Business

Analysts Take Aim at Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) currently has an A verage Broker Rating of -8.43. This number is based on the 2.33 sell-side firms polled by Zacks. The ABR rank within the industry stands at 6.67. Analysts on a consensus basis are expecting that the stock will reach $24.33 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.

Dedicated investors tend to spend a lot of time trying to decipher the correct procedure for beating the stock market. This may involve figuring out a proper strategy, and deciding which stocks to start with when constructing a portfolio. Building a portfolio does not have to be a frantic race. In fact, not rushing into things may end up putting the investor in a good position to succeed. There are times when tough decisions need to be made when dealing with the equity market. Spending enough time to assess all the possibilities before making an investing decision may pay off down the road. As most investors know, there is no magic formula for coming out a winner in the stock market. Acquiring the most possible knowledge about the markets and individual stocks can play a vital role in the long-term success of the individual investor. 

Research analysts are predicting that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will report earnings of $0.08 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) closed the last session at $14.06 and sees an average of 367405 shares trade hands in each session. The 52-week low of the stock stands at $12.66 while the current level stands at 1.26% of the 52-week High-Low range. Looking further out we can see that the stock has moved -17.1% over the past 12 weeks and -27.34% year to date.

Most recently Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted quarterly earnings of $0.07 which compared to the sell-side estimates of 0.05. The stock’s 12-month trailing earnings per share stands at $0.35. Shares have moved $1.10047 over the past month and more recently, $78 over the past week heading into the earnings announcement. There are 3 analyst projections that were taken into consideration from respected brokerage firms.

Investors studying the fundamentals might be conducting in-depth company research before deciding when to purchase a particular stock. The investor checklist may include studying the scope of a company’s competitive industry advantage, examining company management, and trying to get a general feel if the stock is valued properly. Once the decision is made that the company is a good fit for the portfolio, it may be wise to assess whether or not current conditions and price levels indicate proper levels for share purchase. The timing of purchasing a researched stock obviously comes with some level of trepidation. Investors will only know in the future whether they got in at the right price. A stock that looks very attractive today may not be as attractive in the future. Sometimes the investor will just have to trust their research and instinct when purchasing shares. 

3 analysts rate Amphastar Pharmaceuticals, Inc. a Buy or Strong Buy, which is 1% of all the analyst ratings.

Categories
Business

Are Analysts Buzzing Over Amarin Corporation PLC (NASDAQ:AMRN) Shares?

Amarin Corporation PLC (NASDAQ:AMRN) currently has an Average Broker Rating of -21.51. This number is based on the 1.8 sell-side firms polled by Zacks. The ABR rank within the industry stands at 4.71.

Analysts often use a number of terms—buy, strong buy, near-term or long-term accumulate, near-term or long-term over-perform or under-perform, neutral, hold— to describe their recommendations. But the definitions of these terms can differ from company to company. Instead of making assumptions, investors should read the definitions of all ratings used in each analyst report. They should also consider the company’s disclosures regarding what percentage of all ratings fall into either “buy,” “hold/neutral,” and “sell” groups.

Analysts on a consensus basis are expecting that the stock will reach $28.2 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
Research analysts study publicly traded companies and make recommendations on the securities of those companies. Most specialize in a particular industry or sector of the economy. They exert considerable influence in today’s marketplace. Analysts’ recommendations or reports can influence the price of a company’s stock—especially when the recommendations are widely disseminated through television appearances or through other electronic and print media. The mere mention of a company by a popular analyst can temporarily cause its stock to rise or fall—even when nothing about the company’s prospects or fundamentals has recently changed.Technical investors generally rely heavily on price charts to help spot potential trades. Chartists will often try to interpret past movements with the goal of trying to gauge the future share price movements. Some charts can be extremely complex while others may be quite simple. Many traders will spend countless hours studying the signals to try to spot optimal entry and exit points. There are many different indicators that technical analysts can follow. Some traders will use standalone signals, and others will use a robust combination. Getting into the nitty-gritty of charting can be overwhelming for the beginner. Taking the time to completely understand what the charts are saying can be the difference between a big win and a major loss.

Most recently Amarin Corporation PLC (NASDAQ:AMRN) posted quarterly earnings of $0.04 which compared to the sell-side estimates of 0.01. The stock’s 12-month trailing earnings per share stands at $0.02. Shares have moved $2.73193 over the past month and more recently, $14 over the past week heading into the earnings announcement. There are 3 analyst projections that were taken into consideration from respected brokerage firms.

Technical investors generally rely heavily on price charts to help spot potential trades. Chartists will often try to interpret past movements with the goal of trying to gauge the future share price movements. Some charts can be extremely complex while others may be quite simple. Many traders will spend countless hours studying the signals to try to spot optimal entry and exit points. There are many different indicators that technical analysts can follow. Some traders will use standalone signals, and others will use a robust combination. Getting into the nitty-gritty of charting can be overwhelming for the beginner. Taking the time to completely understand what the charts are saying can be the difference between a big win and a major loss.

Buy Ratings
10 analysts rate Amarin Corporation PLC a Buy or Strong Buy, which is 7% of all the analyst ratings.

Earnings
Research analysts are predicting that Amarin Corporation PLC (NASDAQ:AMRN) will report earnings of $-0.04 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Amarin Corporation PLC (NASDAQ:AMRN) closed the last session at $13.24 and sees an average of 9025400 shares trade hands in each session. The 52-week low of the stock stands at $10.23 while the current level stands at 1.11% of the 52-week High-Low range. Looking further out we can see that the stock has moved -9.75% over the past 12 weeks and -38.5% year to date.

Every investor strives to maximize returns in the stock market. To achieve success in the market, investors may take many different paths. Because there are so many different strategies, one investor’s road may end up being quite different than another. Over time, the investor may have to overcome various difficulties. Trading the stock market can indeed be exhilarating, but it can also cause lots of strife. Some investors may be able to be much more aggressive when creating the stock portfolio. Others may have a much lower risk threshold and choose to play it a bit safer. Because humans are prone to error, there may be many mistakes made along the way. Investors who are able to identify mistakes and learn from them may find themselves in a much better position down the road.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.

Categories
Business

Analysts Delving into the Numbers on Allegiant Travel Company (NASDAQ:ALGT) as ABR Moves to 5.55

Allegiant Travel Company (NASDAQ:ALGT) currently has an A verage Broker Rating of -31.39. This number is based on the 1.89 sell-side firms polled by Zacks. The ABR rank within the industry stands at 5.55. Analysts on a consensus basis are expecting that the stock will reach $156.25 within the year.  The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. 

An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.

When active traders find an opening to get in on a stock they think is about to make a move, they may try to buy up as much as they can before the price moves back outside the buying range. This buying may be seen when the stock market dips after a bearish move. Spotting these buying conditions and being able to make a timely move can help the trader take advantage of various market scenarios. Winning traders are typically ready to pounce on any opportunity they find in the stock market.

Allegiant Travel Company (NASDAQ:ALGT) closed the last session at $90.91 and sees an average of 414706 shares trade hands in each session. The 52-week low of the stock stands at $68.82 while the current level stands at 1.21% of the 52-week High-Low range. Looking further out we can see that the stock has moved -30.58% over the past 12 weeks and -48.36% year to date.

Research analysts are predicting that Allegiant Travel Company (NASDAQ:ALGT) will report earnings of $2.59 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.

Most recently Allegiant Travel Company (NASDAQ:ALGT) posted quarterly earnings of $3.72 which compared to the sell-side estimates of 3.87. The stock’s 12-month trailing earnings per share stands at $14.73. Shares have moved $0.82981 over the past month and more recently, $196 over the past week heading into the earnings announcement. There are 5 analyst projections that were taken into consideration from respected brokerage firms.

9 analysts rate Allegiant Travel Company a Buy or Strong Buy, which is 6% of all the analyst ratings.

With so many different stock trading strategies to choose from, new investors may become overwhelmed when presented with all the possible options. Some investors will choose to rely on the expertise of professionals, while others will try to have a go at it on their own. Investors who prefer to do their own research and make their own investment decisions are quite common these days. Of course there is no set in stone way to properly trade the stock market. Markets and economic situations are constantly changing. Staying on top of all the latest information and global developments can be challenging. Investors who are able to stay the course and put in the required time might be able to eventually give themselves a leg up in the future.

This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.